Document KJLyMDdvORx4500GbDeE2v7xr

To: Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com> From: Elizabeth_Moran@americanchemistry.com <E lizabeth_Moran@americanchemistry.com> Cc: Bcc: Received Date: 2006-01-2014:19:05 GMT Subject: RE: Action Items for Peer Review List Development - Please read and act can you provide contact information for Larson and Greim? Elizabeth J. Moran, Ph.D. Senior Director American Chemistry Council 1300 Wilson Blvd Arlington, VA 22209 P: 301 924 2006 F: 301 924 1504 "Cagen, Stuart Z To: "Pottenger, Lynn \(LH\)" SHLOIL-SHOIL-S <LPottenger@dow.com>, HS" <Elizabeth_Moran@americanchemistry.com> <stuart.cagen@ cc: "Bette, home email Moran \(Moran, Bette, shell.com> home email\)..<mwlejm@aol.com>. "'Rawson, Bill' \('Rawson, Bill'\)" <william.rawson@lw.com> 01/19/2006 Subject: RE: Action Items for Peer Review 09:04 PM List Development - Please read and act I would defer to Lynn on her recommendations, including the positive response of Jim Bus regarding Jay Goodman. I think Greim would be excellent but agree he is conflicted. Richard Larson is a leukemia clinician. He is an expert and would appreciate the importance of chromosome abnormalities that are seen in human myelogenous leukemias. He is currently on the Shanghai Peer Review Panel precisely for this reason. Stuart Cagen Shell Health Services One Shell Plaza, 91 0 Louisiana, Houston, TX 77002-4916 Tel: +1 713241 1407 Fax: 3325 Other Tel: +1 8326463987 Email: stuart.cagen@shell.com Internet: http://www.shell.com/chemicals SH ELL-MCCLU RG-055046 .. Business Success through HSSE Excellence" -----Original Message----From: Pottenger, Lynn (LH) [mailto:LPottenger@dow.com] Sent: Thursday, January 19, 2006 7: 13 PM To: 'Elizabeth_Moran@americanchemistry.com' Cc: Cagen, Stuart Z SHLOIL-SHOIL-SHS; Bette, home email Moran (Moran, Bette, home email); 'Rawson, Bill' (,Rawson, Bill') Subject: RE: Action Items for Peer Review List Development - Please read and act Importance: High What happened to my other nominees??? I included the contact info for Jim Tucker (Wayne State University), Dave Eastmond (Univ Calif-Berkeley), and I don't know who Richard Larson is mentioned below, in the previous email, which I've re-attached to this email. You are missing Thomas Loughran, MD (Penn State Cancer Institute), a renowned expert on Large Granular Lymphocytic Leukemia and other leukemias, who participated in an expert panel review/discussion on leukemias with my Dow colleague Dr. Pam Spencer, and was great. Jim Bus felt that Jay Goodman would be very good at this, and I concur. had this info in the previous email ... did you get it? I met Helmut Greim at the HESI mtg and he is very interested in the DNA adduct stuff. I would think that, as past chair of the German MAK commission, he would be conflicted out of this review panel ... n'est pas? Best Regards, Lynn Lynn H. Pottenger, Ph.D., D.A.B.T. TERC The Dow Chemical Company tel: +1 -989-638-7036 fax: +1 -989-638-9863 email: Ipottenger@dow.com -----Original Message----From: Elizabeth_Moran@americanchemistry.com [mailto: Elizabeth_Moran@americanchemistry.com] Sent: Thursday, January 19, 20066:52 PM To: stuart.cagen@shell.com; david.dutton@innovene.com; Ray-Papciak@huntsman.com; Pottenger, Lynn (LH); william.rawson@lw.com; Marcy. Banton@ Lyondell. com; mwlej m @aol.com; Shelby-Jones@americanchemistry.com; leeji@cpchem.com; michael.g.bird@exxonmobil.com; r.jeffrey.lewis@exxonmobil.com; a.r.schnatter@exxonmobil.com Subject: Action Items for Peer Review List Development - Please read and SH ELL-MCCLU RG-055047 act W. Rawson, E. Moran and S. Cagen will review the final draft risk assessment report prior to transmitting it to the peer review leadership team. THE FOLLOWING SCIENTISTS WERE IDENTIFIED AS PEER REVIEW NOMINEES: Harvey Checkoway David Coglin Gary Marshall Tucker? Wayne State University David Eastman? Jefferson Richard Larson? University of Chicago Medical School Helmut Grime? Germany The follow plan was designed to develop a more complete list of nominated peer reviewers: L. Pottenger will send contact information for Marshall, Tucker, Eastman and Larson. S. Cagen will send contact information for Checkoway. J. Lewis will consult with M. Bird and provide additional nominations. E. Moran will request suggestions for peer reviewers from the Risk Assessment Team. L. Pottenger will discuss additional scientists with J. Bus. J. Lewis will talk to R. Schnatter about experts in leukemia. E. Moran will compile the list and circulate to the BWG for final review. E. Moran will contact T. Scalli and update him on the status of the risk assessment. W. Rawson will contact L. Hulse regarding the status of the residual risk rule for the HON category. W. Rawson will develop the first draft of possible charge questions to suggest to Sciences International and circulate them for BWG comment. Elizabeth J. Moran, Ph.D. Senior Director American Chemistry Council 1300 Wilson Blvd Arlington, VA 22209 P: 301 924 2006 F: 301 924 1504 SH ELL-MCCLU RG-055048 SH ELL-MCCLU RG-055049